Sanekommu Harshavardhan, Taj Sobaan, Mah Noor Rida, Umair Akmal Muhammad, Akhtar Reza, Hossain Mohammad, Asif Arif
Department of Medicine, Jersey Shore University Medical Center, 1945 NJ-33, Neptune City, NJ 07753, USA.
School of Medicine, Eastern Campus, International University of Kyrgyzstan-International, Bishkek 720007, Kyrgyzstan.
Clin Pract. 2023 Aug 1;13(4):881-888. doi: 10.3390/clinpract13040080.
Chronic kidney disease (CKD) is a global health challenge affecting nearly 700 million people worldwide. In the United States alone, the Medicare costs for CKD management has reached nearly USD 80 billion per year. While reversing CKD may be possible in the future, current strategies aim to slow its progression. For the most part, current management strategies have focused on employing Renin Angiotensin Aldosterone (RAS) inhibitors and optimizing blood pressure and diabetes mellitus control. Emerging data are showing that a disruption of the gut-kidney axis has a significant impact on delaying CKD progression. Recent investigations have documented promising results in using microbiota-based interventions to better manage CKD. This review will summarize the current evidence and explore future possibilities on the use of probiotics, prebiotics, synbiotics, and fecal microbial transplant to reduce CKD progression.
慢性肾脏病(CKD)是一项全球性的健康挑战,影响着全球近7亿人。仅在美国,慢性肾脏病管理的医疗保险费用每年就已达到近800亿美元。虽然未来逆转慢性肾脏病或许是可能的,但目前的策略旨在减缓其进展。在很大程度上,当前的管理策略集中于使用肾素-血管紧张素-醛固酮(RAS)抑制剂以及优化血压和糖尿病控制。新出现的数据表明,肠-肾轴的破坏对延缓慢性肾脏病进展具有重大影响。最近的研究记录了使用基于微生物群的干预措施来更好地管理慢性肾脏病的有前景的结果。本综述将总结当前证据,并探讨使用益生菌、益生元、合生元和粪便微生物移植来降低慢性肾脏病进展的未来可能性。